Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development.
Fiche publication
Date publication
décembre 2021
Journal
Gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Dr CROUCHET Emilie
Tous les auteurs :
Qian T, Fujiwara N, Koneru B, Ono A, Kubota N, Jajoriya AK, Tung MG, Crouchet E, Song WM, Marquez CA, Panda G, Hoshida A, Raman I, Li QZ, Lewis C, Yopp A, Rich NE, Singal AG, Nakagawa S, Goossens N, Higashi T, Koh AP, Bian CB, Hoshida H, Tabrizian P, Gunasekaran G, Florman S, Schwarz ME, Hiotis SP, Nakahara T, Aikata H, Murakami E, Beppu T, Baba H, Warren A, Bhatia S, Kobayashi M, Kumada H, Fobar AJ, Parikh ND, Marrero JA, Rwema SH, Nair V, Patel M, Kim-Schulze S, Corey K, O'Leary JG, Klintmalm GB, Thomas DL, Dibas M, Rodriguez G, Zhang B, Friedman SL, Baumert TF, Fuchs B, Chayama K, Zhu S, Chung RT, Hoshida Y
Lien Pubmed
Résumé
There is a major unmet need to assess the prognostic impact of anti-fibrotics in clinical trials due to the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future fibrosis progression.
Mots clés
Prognostic prediction, companion biomarker, drug development, liver fibrosis
Référence
Gastroenterology. 2021 Dec 21;: